Comprehensive Genomic Profiling (CGP) In the U.S. - Executive Director in Translational Oncology, Top 10 Pharma

An executive director at a top pharma company shares their experience with the expansion of CGP, emphasizing the need for larger panels and greater genomic coverage. The stakeholder considers the coverage of all common variant types critical and recombination repair signatures increasingly important. They also mention the importance of assessing specific promoters and their loss of expression as relevant in subsets of patients for better treatment understanding and expanded indications. The stakeholder perceives CGP as important in their current role, particularly for clinical trials where central confirmation of mutations or a diagnostic is required. They expect advancements in CGP technology, particularly for blood samples, and they anticipate a shift towards more powerful liquid biopsy tests. Overall, the stakeholder perceives CGP as a valuable tool in their work and acknowledges the need for improvements in technology and sample quality to address existing challenges.

‍